Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
-0.020 (-4.26%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.43 - 0.49
52 week 0.28 - 2.49
Open 0.49
Vol / Avg. 0.00/13.25M
Mkt cap 90.41M
P/E     -
Div/yield     -
EPS -0.26
Shares 209.84M
Beta 1.88
Inst. own 13%
Sep 11, 2016
Galena Biopharma Inc at Rodman & Renshaw Global Investment Conference Add to calendar
Aug 4, 2016
Q2 2016 Galena Biopharma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 14, 2016
Galena Biopharma Inc Annual Shareholders Meeting
Jul 8, 2016
Galena Biopharma Inc Conference Call to Discuss Interim Analysis on Phase 3 Trial and Update on Clinical Development Programs
Jun 17, 2016
Galena Biopharma Inc Annual Shareholders Meeting (Estimated)
Jun 3, 2016
Galena Biopharma Inc at Sachs Immuno-Oncology: BD&L and Investment Forum
May 10, 2016
Q1 2016 Galena Biopharma Inc Earnings Call
May 10, 2016
Q1 2016 Galena Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -70.77% -47.91%
Return on average equity -405.40% -154.06%
Employees 22 -
CDP Score - -


4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark W. Schwartz President, Chief Executive Officer, Independent Director
Age: 59
Bio & Compensation  - Reuters
Bijan Nejadnik M.D. Executive Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
John Thomas Burns Principal Accounting Officer
Age: 30
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 72
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters